CA2131150A1 - Complexes de recepteurs avec b29 (ig-beta ou ig-gamma), et leurs utilisations - Google Patents

Complexes de recepteurs avec b29 (ig-beta ou ig-gamma), et leurs utilisations

Info

Publication number: CA2131150A1
Authority: CA; Canada
Prior art keywords: accordance; igm; cells; lymphocytes; expression
Prior art date: 1992-03-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002131150A

Other languages

English (en)

Inventor

Michel C. Nussenzweig

Thais E. Costa

Roland R. Franke

Mercedes Sanchez

Ziva Misulovin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Rockefeller University

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-03

Filing date

1993-03-03

Publication date

1993-09-16

1993-03-03 Application filed by Individual filed Critical Individual

1993-09-16 Publication of CA2131150A1 publication Critical patent/CA2131150A1/fr

Status Abandoned legal-status Critical Current

Links

101710166261 B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 title description 2
102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 title description 2
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 120
210000004027 cell Anatomy 0.000 claims abstract description 118
108090000623 proteins and genes Proteins 0.000 claims abstract description 115
102000004169 proteins and genes Human genes 0.000 claims abstract description 75
238000000034 method Methods 0.000 claims abstract description 67
108060003951 Immunoglobulin Proteins 0.000 claims abstract description 66
102000018358 immunoglobulin Human genes 0.000 claims abstract description 66
210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 50
239000000427 antigen Substances 0.000 claims abstract description 43
108091007433 antigens Proteins 0.000 claims abstract description 41
102000036639 antigens Human genes 0.000 claims abstract description 41
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 34
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
229920001184 polypeptide Polymers 0.000 claims abstract description 33
210000003630 histaminocyte Anatomy 0.000 claims abstract description 30
210000002540 macrophage Anatomy 0.000 claims abstract description 25
230000000694 effects Effects 0.000 claims abstract description 22
102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims abstract description 4
101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims abstract description 4
108020003175 receptors Proteins 0.000 claims description 95
102000005962 receptors Human genes 0.000 claims description 95
101000985635 Homo sapiens Protein maestro Proteins 0.000 claims description 90
102100028703 Protein maestro Human genes 0.000 claims description 90
235000018102 proteins Nutrition 0.000 claims description 73
230000014509 gene expression Effects 0.000 claims description 72
230000027455 binding Effects 0.000 claims description 46
238000009739 binding Methods 0.000 claims description 46
239000012634 fragment Substances 0.000 claims description 39
229950004354 phosphorylcholine Drugs 0.000 claims description 32
108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
108020004414 DNA Proteins 0.000 claims description 23
206010028980 Neoplasm Diseases 0.000 claims description 23
239000013604 expression vector Substances 0.000 claims description 20
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 18
241000700605 Viruses Species 0.000 claims description 17
239000003937 drug carrier Substances 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 17
230000004044 response Effects 0.000 claims description 17
150000001875 compounds Chemical class 0.000 claims description 15
150000001413 amino acids Chemical class 0.000 claims description 10
239000012528 membrane Substances 0.000 claims description 10
230000011664 signaling Effects 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 8
230000003185 calcium uptake Effects 0.000 claims description 8
230000001419 dependent effect Effects 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
230000007306 turnover Effects 0.000 claims description 8
235000001014 amino acid Nutrition 0.000 claims description 7
229940024606 amino acid Drugs 0.000 claims description 7
108010075597 immunoglobulin M receptor Proteins 0.000 claims description 7
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
238000012216 screening Methods 0.000 claims description 5
208000036142 Viral infection Diseases 0.000 claims description 4
230000009385 viral infection Effects 0.000 claims description 4
206010062207 Mycobacterial infection Diseases 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
208000027531 mycobacterial infectious disease Diseases 0.000 claims description 3
YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 3
210000004881 tumor cell Anatomy 0.000 claims description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
230000036039 immunity Effects 0.000 claims description 2
230000003071 parasitic effect Effects 0.000 claims description 2
230000002458 infectious effect Effects 0.000 claims 3
244000045947 parasite Species 0.000 claims 3
108010041397 CD4 Antigens Proteins 0.000 claims 2
241000725303 Human immunodeficiency virus Species 0.000 claims 2
208000030852 Parasitic disease Diseases 0.000 claims 2
208000031886 HIV Infections Diseases 0.000 claims 1
208000037357 HIV infectious disease Diseases 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
238000003306 harvesting Methods 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
230000002519 immonomodulatory effect Effects 0.000 claims 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
230000036281 parasite infection Effects 0.000 claims 1
102000006306 Antigen Receptors Human genes 0.000 abstract description 10
108010083359 Antigen Receptors Proteins 0.000 abstract description 10
238000006243 chemical reaction Methods 0.000 abstract description 7
230000001225 therapeutic effect Effects 0.000 abstract description 7
239000000203 mixture Substances 0.000 abstract description 6
238000002405 diagnostic procedure Methods 0.000 abstract description 3
230000028993 immune response Effects 0.000 abstract description 3
238000002560 therapeutic procedure Methods 0.000 abstract description 3
101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 79
101150011109 mbl gene Proteins 0.000 description 54
239000003446 ligand Substances 0.000 description 31
YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 29
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 27
108091008874 T cell receptors Proteins 0.000 description 20
239000013612 plasmid Substances 0.000 description 20
238000003556 assay Methods 0.000 description 19
108020004999 messenger RNA Proteins 0.000 description 19
239000002299 complementary DNA Substances 0.000 description 18
230000019491 signal transduction Effects 0.000 description 18
239000013598 vector Substances 0.000 description 18
239000012491 analyte Substances 0.000 description 14
238000004132 cross linking Methods 0.000 description 14
108010002350 Interleukin-2 Proteins 0.000 description 13
102000000588 Interleukin-2 Human genes 0.000 description 13
239000000463 material Substances 0.000 description 13
108091003079 Bovine Serum Albumin Proteins 0.000 description 12
229940098773 bovine serum albumin Drugs 0.000 description 12
239000000523 sample Substances 0.000 description 11
102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 10
241000283707 Capra Species 0.000 description 10
230000004913 activation Effects 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
102000002265 Human Growth Hormone Human genes 0.000 description 9
108010000521 Human Growth Hormone Proteins 0.000 description 9
239000000854 Human Growth Hormone Substances 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
241000713880 Spleen focus-forming virus Species 0.000 description 8
-1 e.g. Proteins 0.000 description 8
229960000367 inositol Drugs 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
230000028327 secretion Effects 0.000 description 8
238000001890 transfection Methods 0.000 description 8
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 7
230000032258 transport Effects 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
238000001514 detection method Methods 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
210000002950 fibroblast Anatomy 0.000 description 6
230000002285 radioactive effect Effects 0.000 description 6
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
239000011324 bead Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000007969 cellular immunity Effects 0.000 description 5
229940072221 immunoglobulins Drugs 0.000 description 5
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
238000012546 transfer Methods 0.000 description 5
230000014616 translation Effects 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 4
ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 4
ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 4
102000008072 Lymphokines Human genes 0.000 description 4
108010074338 Lymphokines Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
229930193140 Neomycin Natural products 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 4
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000004520 electroporation Methods 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
229960004927 neomycin Drugs 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 4
108091092562 ribozyme Proteins 0.000 description 4
241000894007 species Species 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 3
108091008875 B cell receptors Proteins 0.000 description 3
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 3
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
108091035707 Consensus sequence Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
108700005091 Immunoglobulin Genes Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
230000006044 T cell activation Effects 0.000 description 3
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000003149 assay kit Methods 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000004186 co-expression Effects 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000000984 immunochemical effect Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000012160 loading buffer Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000005259 measurement Methods 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
238000011160 research Methods 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010015776 Glucose oxidase Proteins 0.000 description 2
239000004366 Glucose oxidase Substances 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010089430 Phosphoproteins Proteins 0.000 description 2
102000007982 Phosphoproteins Human genes 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 2
108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
108700010039 chimeric receptor Proteins 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000007878 drug screening assay Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940116332 glucose oxidase Drugs 0.000 description 2
235000019420 glucose oxidase Nutrition 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000004073 interleukin-2 production Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000006166 lysate Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000035772 mutation Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
102100026445 A-kinase anchor protein 17A Human genes 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108010005094 Advanced Glycation End Products Proteins 0.000 description 1
241001514645 Agonis Species 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101100285518 Drosophila melanogaster how gene Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
240000003550 Eusideroxylon zwageri Species 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
241000233866 Fungi Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
101150083678 IL2 gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
102100038609 Lactoperoxidase Human genes 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108091005461 Nucleic proteins Chemical group 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
108010070783 alanyltyrosine Proteins 0.000 description 1
230000004075 alteration Effects 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
238000002820 assay format Methods 0.000 description 1
JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
230000011712 cell development Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
210000005220 cytoplasmic tail Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
108091005979 iodinated proteins Proteins 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229930029653 phosphoenolpyruvate Natural products 0.000 description 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
210000001948 pro-b lymphocyte Anatomy 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000007727 signaling mechanism Effects 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Public Health (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Developmental Biology & Embryology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)

CA002131150A 1992-03-03 1993-03-03 Complexes de recepteurs avec b29 (ig-beta ou ig-gamma), et leurs utilisations Abandoned CA2131150A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84510192A	1992-03-03	1992-03-03
US07/845,101		1992-03-03

Publications (1)

Publication Number	Publication Date
CA2131150A1 true CA2131150A1 (fr)	1993-09-16

Family

ID=25294401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002131150A Abandoned CA2131150A1 (fr)	1992-03-03	1993-03-03	Complexes de recepteurs avec b29 (ig-beta ou ig-gamma), et leurs utilisations

Country Status (5)

Country	Link
EP (1)	EP0631624A1 (fr)
JP (1)	JPH07504817A (fr)
AU (1)	AU3992597A (fr)
CA (1)	CA2131150A1 (fr)
WO (1)	WO1993018161A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5733540A (en) *	1995-03-08	1998-03-31	Lee; Peter Poon-Hang	Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
WO2001085205A1 (fr) *	2000-05-11	2001-11-15	National Tsing Hua University	Compositions et procedes concourant a l'induction d'une auto-immunite active
WO2005100405A2 (fr)	2004-04-15	2005-10-27	Athera Biotechnologies Ab	Nouvelle composition
HRP20190988T1 (hr)	2011-08-09	2019-09-20	Athera Biotechnologies Ab	Nova protutijela protiv fosforilkolina
CN103906532B (zh)	2011-08-09	2018-01-26	阿瑟拉生物技术公司	结合磷酰胆碱（pc）和/或pc结合物的抗体
WO2016062898A1 (fr) *	2014-10-24	2016-04-28	Bcrt Holding Bv	Agents immunothérapeutiques à base de cellules t
WO2017186853A1 (fr) *	2016-04-27	2017-11-02	Bcrt Holding Bv	Agents immunothérapeutiques bispécifiques à base de cellules t

1993
- 1993-03-03 JP JP5515835A patent/JPH07504817A/ja active Pending
- 1993-03-03 WO PCT/US1993/001865 patent/WO1993018161A1/fr not_active Ceased
- 1993-03-03 EP EP93907136A patent/EP0631624A1/fr not_active Withdrawn
- 1993-03-03 CA CA002131150A patent/CA2131150A1/fr not_active Abandoned
1997
- 1997-10-03 AU AU39925/97A patent/AU3992597A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1993018161A1 (fr)	1993-09-16
JPH07504817A (ja)	1995-06-01
AU3992597A (en)	1998-02-12
EP0631624A1 (fr)	1995-01-04

Publication	Publication Date	Title
US5820866A (en)	1998-10-13	Product and process for T cell regulation
Allen et al.	1986	Beta 2-microglobulin is not required for cell surface expression of the murine class I histocompatibility antigen H-2Db or of a truncated H-2Db.
Hudson et al.	1993	Two adjacent residues in staphylococcal enterotoxins A and E determine T cell receptor V beta specificity.
Robinson et al.	1989	A glycophospholipid anchor is required for Qa-2-mediated T cell activation
JP2657221B2 (ja)	1997-09-24	ヒトＦｃγレセプター▲ＩＩＩ▼
US7223852B2 (en)	2007-05-29	Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family
Matsuuchi et al.	1992	The membrane IgM-associated proteins MB-1 and Ig-beta are sufficient to promote surface expression of a partially functional B-cell antigen receptor in a nonlymphoid cell line.
JP2002504818A (ja)	2002-02-12	リガンドファミリーのｎｔｎ−２メンバー
Saito et al.	1987	Predictable acquisition of a new MHC recognition specificity following expression of a transfected T-cell receptor β-chain gene
JPH11507843A (ja)	1999-07-13	タンパク質の可溶性二価および多価ヘテロ二量体類縁体
EP0741788B1 (fr)	2005-02-02	Induction d'une tolerance au moyen de proteines de fusion tolerogenes
WO1998055621A1 (fr)	1998-12-10	Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
CA2181062A1 (fr)	1995-08-03	Diagnostic de cancers metastasiques a l'aide du gene mts-1
WO1995010628A2 (fr)	1995-04-20	Transduction de signaux par l'intermediaire de cd28
KR20080090413A (ko)	2008-10-08	Ｔ 조절 세포의 확장을 위한 방법 및 조성물
JP2001519143A (ja)	2001-10-23	可溶性の一本鎖ｔ細胞レセプタータンパク質
CA2116339A1 (fr)	1993-03-18	Reactifs specifiques pour le recepteur v.alpha.12.1 t des cellules utiles, pour le diagnostic et le traitement du rhumatisme chronique deformant
JPH10511265A (ja)	1998-11-04	新規タンパク質チロシンキナーゼ、ｊａｋ３
Costa et al.	1992	Functional reconstitution of an immunoglobulin antigen receptor in T cells.
JP2001507219A (ja)	2001-06-05	単離された哺乳動物単球細胞遺伝子；関連する試薬
Ballhausen et al.	1988	Acquisition of an additional antigen specificity after mouse CD4 gene transfer into a T helper hybridoma.
US5552537A (en)	1996-09-03	IgE isoforms and methods of use
US6500430B1 (en)	2002-12-31	Product and process to regulate actin polymerization in T lymphocytes
JP2009005699A (ja)	2009-01-15	活性化レセプタに会合される新しいポリペプチド及びその生物学的応用
CA2131150A1 (fr)	1993-09-16	Complexes de recepteurs avec b29 (ig-beta ou ig-gamma), et leurs utilisations

Legal Events

Date	Code	Title	Description
2000-03-03	FZDE	Discontinued